Mindpeak, the leading innovator in Artificial Intelligence (AI) software for pathology, unveiled a new product to empower pathologists in detecting and grading prostate cancer. The AI was developed by Clinsight AB, a Swedish company founded in 2022 as a spin out from Karolinska Institutet. The finished software solution was co-developed with Mindpeak for seamless analysis of digitized prostate slides.

The new AI software is designed to analyze digital histopathology images of prostate needle biopsies, pinpointing areas that are suspicious for cancer and grading the malignancies according to Gleason scoring.

The prostate AI software was developed using diagnostic specimens from an international network of 12 clinical sites. It has been trained and validated on over 80,000 whole slide images from 13 slide scanner models, achieving outstanding accuracy and generalization. A preprint of the research study protocol is available at MedRxIv and earlier results forming the basis for Clinsight’s AI development have been  published in The Lancet Oncology and Nature Medicine.

With the newly published product, Mindpeak expands its portfolio to over 15 solutions covering cancer types from breast, prostate, gastric, lung, bladder, and skin.

“With approximately 12.8 percent of men being diagnosed with prostate cancer at some point in their lifetime which is looking to double in the next 15 years, the demand for advanced precision medicine tools that provide accurate biological insights has never been greater. An AI system with expert-level grading performance could offer a second opinion, aid in standardizing grading, and provide pathology expertise in regions where it is lacking.“

said Felix Faber, CEO of Mindpeak.

About Mindpeak

Mindpeak is the leading innovator in AI software for pathology, with over 30,000 patients diagnosed globally and >20 scientific publications. Specializing in advanced tissue biomarker analysis, Mindpeak offers tools that support clinical laboratories and biopharma companies.
Their AI algorithms were among the first used in digital pathology for routine clinical diagnostics in both the USA and EU.

The prostate product is currently labeled as research use only (RuO) and not approved for diagnostic purposes.